Patent Assignment
Reel/Frame 013898/0170
Assignment of Assignor's Interest
Recorded: 2003-04-07
Pages: 17
Assignor
ALLERGAN SALES, INC. (MERGED INTO ALLERGAN SALES, LLC 6/3/2002)
Executed: 2003-03-31
Assignee
ALLERGAN, INC.
2525 DUPONT DRIVE, IRVINE, CALIFORNIA, 92612
Covered Properties
(108)
Method of Identifying Hormone Receptor Ligands
Application:
09/108,298 →
Tazarotene and Alpha Hydroxy Acid Treatment for Psoriasis and /or Photodamage
Patent:
6,730,308 →
Application:
09/264,531 →
Methods and Compositions for the Treatment of Pancreatitis
Compositions and Methods for Modulating Neural Sprouting
Application:
09/294,980 →
Compounds and Methods of Treatment Having Agonist-Like Activity Selective at Alpha 2B or 2B/2C Adrenergic Receptors
Application:
09/329,752 →
Tazarotene and Corticosteroid Treatment for Psoriasis
Patent:
6,974,807 →
Application:
09/367,712 →
Intrapericardial Botulinum Toxin Treatment for Bradycardia
Patent:
6,977,080 →
Application:
09/371,354 →
Clostridial Toxin Derivatives and Methods for Treating Pain
Patent:
7,138,127 →
Application:
09/489,667 →
Botulinum toxin pharmaceutical compositions
Application:
09/500,147 →
Amines Substituted with a Dihydronaphthalenyl, Chromenyl, or Thiochromenyl Group, an Aryl or Heteroaryl Group and an Alkyl Group, Having Retinoid-Like Biological Activity
Patent:
6,613,917 →
Application:
09/533,680 →
Methods and compositions for modulating alpha adrenergic receptor activity
Application:
09/548,315 →
Methods and Compositions for the Treatment of Pancreatitis
Patent:
6,843,998 →
Application:
09/548,409 →
Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
Application:
09/552,823 →
Publication:
US 2003/0114482
Methods for Treating Bone Tumors
Patent:
6,565,870 →
Application:
09/561,106 →
Methods for Modulating Fxr Receptor Activity
Patent:
6,906,057 →
Application:
09/590,447 →
Compositions Including Antibiotics and Methods for Using Same
Patent:
6,552,020 →
Application:
09/624,129 →
Bone Tumor Pain Treatment
Patent:
6,641,820 →
Application:
09/625,098 →
Treatment of Tumors with Acetylenes Disubstituated with a Phenyl or Heteroaromatic Group and a Substituted Chromanyl, Thiochromanyl or Tetrahydroquinolinyl Group in Combination with Other Anti-Tumor Agents
Patent:
6,903,121 →
Application:
09/640,852 →
Activatable Recombinant Neurotoxins
Patent:
7,132,259 →
Application:
09/648,692 →
Compounds having activity as inhibitors of cytochrome P450RAI
Patent:
6,252,090 →
Application:
09/651,235 →
Method for Treating Endocrine Disorders
Patent:
6,827,931 →
Application:
09/692,811 →
Method for Treating Parathyroid Disorders
Patent:
6,649,161 →
Application:
09/704,464 →
Method for Treating Hyperthyroidism
Patent:
6,743,424 →
Application:
09/706,172 →
Method for Treating Hypothyroidism
Patent:
6,585,970 →
Application:
09/706,173 →
Method for Treating Thyroid Disorders
Patent:
6,740,321 →
Application:
09/706,211 →
Method for Treating Thyroid Disorders
Patent:
6,716,427 →
Application:
09/706,215 →
Neurotoxins with Enhanced Target Specificity
Agent and Methods for Treating Pain
Patent:
6,787,517 →
Application:
09/751,053 →
Capsule System
Methods and Compositions for Modulating Alpha Adrenergic Receptor Activity
Compositions and Methods for Treating Gonadotrophin Related Illnesses
Methods of detecting dissociated nuclear hormone receptor ligands
Application:
09/814,604 →
Publication:
US 2003/0003517
Identification of nuclear receptor-dependent coregulator recruitment
Application:
09/815,156 →
Publication:
US 2002/0037514
Imidiazoles Having Reduced Side Effects
Hypoparthyroid Therapy
Methods for Reducing Non-Inflammatory Pain
Compositions having enhanced pharmacokinetic characteristics
Application:
09/847,935 →
Publication:
US 2002/0198209
Methods of treating hyperlipidemia
Application:
09/848,159 →
Publication:
US 2002/0193403
Alpha-2-Adrenergic Agonist/Fatty Acid Compositions
Application:
09/848,249 →
Publication:
US 2002/0198210
Stable RXR expressing cell line
Application:
09/850,835 →
Publication:
US 2003/0228632
3, 7OR3 and 7 Thia or Oxa Prostanoic Acid Derivatives as Agents for Lowering Intraocular Pressure
Application:
09/882,720 →
Publication:
US 2003/0027853
Methods of Identifying Ocular Hypotensive Compounds Having Reduced Hyperpigmentation
Combinations of prostaglandins and brimonidine or derivatives thereof
Application:
09/903,954 →
Publication:
US 2002/0010202
Compositions Containing Alpha-2-Adrenergic Agonist Components
Use of Antimicrobial Peptides as Preservatives in Ophthalmic Preparations, Including Solutions, Emulsions, and Suspensions
Flip top piercing tip cap
Application:
09/918,847 →
Publication:
US 2003/0024947
Methods and compositions for the treatment and prevention of lung disease
Application:
09/919,195 →
Publication:
US 2001/0053758
Methods of screening for compounds that modulate hormone receptor activity
Application:
09/922,226 →
Publication:
US 2003/0077664
Botulinum Neurotoxin-Substance P Conjugate or Fusion Protein for Treating Pain
Fret Protease Assays for Botulinum Serotype a/E Toxins
Fret Protease Assays for Clostridial Toxins
Methods for Treating Fibromyalgia
Recombinant simian GPR3 receptor
Application:
09/956,470 →
Publication:
US 2002/0177190
Method for Treating Primary Hyperparathyroid Disorders
Preserved Cyclodextrin-Containing Compositions
Methods of Treatment with Compounds Having Rar Alpha Receptor Specific or Selective Activity
Methods and compositions for treatment of ocular neovascularization and neural injury
Application:
09/998,718 →
Publication:
US 2002/0094998
Modified clostridial neurotoxins with altered biological persistence
Application:
10/004,230 →
Publication:
US 2002/0127247
Method for Treating a Mucus Secretion
Methods for Measuring Retinal Damage
Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
Application:
10/016,850 →
Publication:
US 2003/0114460
Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
Application:
10/017,660 →
Publication:
US 2002/0137777
Ophthalmic Compositions for Lubricating Eyes and Methods for Making and Using Same
Botulinum Toxin Therapy for Hashimoto's Thyroiditis
Methods and Compositions for Treatment of Ocular Neovascularization and Neural Injury
Application:
10/020,541 →
Publication:
US 2003/0082183
Calcium Blockers to Treat Proliferative Vitreoretinopathy
Dual channel remote terminal
Application:
10/039,520 →
Publication:
US 2003/0076853
Methods of treating animals with botulinum toxin pharmaceutical compositions
Application:
10/047,058 →
Publication:
US 2002/0064536
Methods of Administering Botulinum Toxin
Methods for Treating Mammary Gland Disorders
1-Imidazolyl Substituted Tetrahydronaphthalene Derivatives as Inhibitors of P450RAI
Methods of extending corneal graft survival
Application:
10/081,126 →
Publication:
US 2003/0180294
Method for Treating Neurogenic Inflammation Pain with Botulinum Toxin and Substance P Components
Compounds having activity as inhibitors of cytochrome P450RAI
Application:
10/097,315 →
Publication:
US 2002/0183285
Compounds having activity as inhibitors of cytochrome P450RAI
Application:
10/097,368 →
Publication:
US 2002/0160986
Clostridial Toxin Therapy for Hashimoto's Thyroiditis
Photodynamic Therapy for Pre-Melanomas
Method for Determining Effect of a Clostridial Toxin Upon a Muscle
4-[(8-Ethynyl, 8-Vinyl or 8-Ethynyl-Methyl)-6-Chromanoyl]-Benzoic and 2-[4-[(8-Ethynyl, 8-Vinyl or 8-Ethynyl-Methyl)-6-Chromanoyl]-Phenyl]-Acetic Acid, Their Esters and Salts Having Cytochrome P450RAI Inhibitory Activity
3, 7 or 3 and 7 Thia or Oxa Prostanoic Acid Derivatives as Agents for Lowering Intraocular Pressure
Patent:
6,538,018 →
Application:
10/103,301 →
Composition and method for modulating BAR/FXR receptor activity
Application:
10/104,385 →
Publication:
US 2003/0144360
Omega-Cycloalkyl 17-Heteroaryl Prostaglandin E2 Analogs as EP2-Receptor Agonists
Methods and Compositions for the Treatment of Cerebral Palsy
Antibodies Directed Towards a Novel Human Ep Prostaglandin Receptor
Methods for Treating Cardiovasular Diseases with Botulinum Toxin
Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
Application:
10/116,492 →
Publication:
US 2002/0183368
Disinfecting and solubilizing steroid compositions
Application:
10/121,076 →
Publication:
US 2002/0198174
Compositions Including Vitamin-Based Surfactants and Methods for Using Same
Compositions for Treating Hyperemia
Dihydrobenzofuran and Dihydrobenzothiophene 2,4-Pentadienoic Acid Derivatives Having Selective Activity for Retinoid X (Rxr) Receptors
Container for product integrity and identification
Application:
10/143,076 →
Publication:
US 2003/0211259
Therapeutic Treatments for Neuropsychiatric Disorders
8-Azaprostaglandin Analogs as Agents for Lowering Intraocular Pressure
Patent:
6,573,294 →
Application:
10/146,224 →
Therapy for Injured Muscles
Antibiotic compositions and methods for using same
Application:
10/194,834 →
Publication:
US 2003/0073694
Pain Treatment by Peripheral Administration of a Neurotoxin
Methods of Providing and Using Compounds Having Activity as Inhibitors of Cytochrome P450RAI
Compositions Containing Alpha-2-Adrenergic Agonist Components
Compositions including antibiotics and methods for using same
Application:
10/236,712 →
Publication:
US 2003/0114464
Prostanoic Acid Derivatives as Agents for Lowering Intraocular Pressure
Compositions Containing Alpha-2-Adrenergic Agonist Components
Interheteroaryl 7-Oxabicyclic [2.2.1]Heptane Oxazoles as Prostaglandin F2ALPHA Antagonists
Male anti-fertility agents
Application:
10/304,665 →
Publication:
US 2003/0144256
Methods and compositions for the treatment and prevention of lung disease
Application:
10/305,049 →
Publication:
US 2003/0078294
3, 7 or 3 and 7 Thia or Oxa Prostanoic Acid Derivatives as Agents for Lowering Intraocular Pressure
Methods of treating animals with botulinum toxin pharmaceutical compositions
Application:
10/360,098 →
Publication:
US 2003/0138460
Compounds Having Activity as Inhibitors of Cytochrome P450RAI
Method for treating a non-rhinorrhea cholinergic influenced secretion
Application:
10/365,082 →
Publication:
US 2003/0157134
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 28, 1999
From: NAGPAL, SUNIL; CHANDRARATNA, ROSHANTHA A.; GHOSN, CORINE
To: ALLERGAN SALES, INC.
Reel/Frame 009718/0278 →
Assignment of Assignor's Interest
Mar 8, 1999
From: SEFTON, JOHN
To: ALLERGAN SALES, INC.
Reel/Frame 009820/0106 →
Assignment of Assignor's Interest
Apr 23, 1999
From: SACHS, GEORGE; AOKI, KEI ROGER
To: ALLERGAN SALES, INC.
Reel/Frame 009910/0697 →
Assignment of Assignor's Interest
Jun 28, 1999
From: AOKI, KEI ROGER
To: ALLERGAN SALES, INC.
Reel/Frame 010054/0849 →
Assignment of Assignor's Interest
Jun 28, 1999
From: DOLLY, OLIVER; DE PAIVA, ANTON
To: IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE OF LONDON
Reel/Frame 010054/0941 →
Assignment of Assignor's Interest
Jun 28, 1999
From: IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
To: ALLERGAN SALES, INC.
Reel/Frame 010054/0854 →
Assignment of Assignor's Interest
Aug 13, 1999
From: CHOW, KEN; GIL, DANIEL W.; BURKE, JAMES A.; HARCOURT, DALE A.
To: ALLERGAN SALES, INC.
Reel/Frame 010166/0035 →
Assignment of Assignor's Interest
Feb 28, 2000
From: STANFORD, CARL R.
To: LIFETIME PRODUCTS, INC.
Reel/Frame 010647/0081 →
Assignment of Assignor's Interest
Mar 23, 2000
From: BEARD, RICHARD L.; VU, THONG; COLON, DIANA F.; VULIGONDA, VIDYASAGAR
To: ALLERGAN SALES, INC.
Reel/Frame 010690/0448 →
Assignment of Assignor's Interest
Apr 13, 2000
From: CHOW, KEN; GIL DANIEL W.; FANG, WENKUI KEN; GARST, MICHAEL E.
To: ALLERGAN SALES, INC.
Reel/Frame 010748/0138 →
Assignment of Assignor's Interest
Apr 13, 2000
From: STEWARD, LANCE E.; SACHS, GEORGE; AOKI, KEI ROGER
To: ALLERGAN SALES, INC.
Reel/Frame 010726/0276 →
Assignment of Assignor's Interest
Apr 20, 2000
From: PACIFICI, MAURIZIO; CHANDRARATNA, ROSHANTHA A.
To: ALLERGAN, INC.
Reel/Frame 010755/0358 →
Assignment of Assignor's Interest
Apr 26, 2000
From: DONOVAN, STEPHEN
To: ALLERGAN SALES, INC.
Reel/Frame 010780/0132 →
Assignment of Assignor's Interest
Apr 28, 2000
From: DONOVAN, STEPHEN
To: ALLERGAN SALES, INC.
Reel/Frame 010779/0459 →
Assignment of Assignor's Interest
May 1, 2000
From: DONOVAN, STEPHEN
To: ALLERGAN SALES, INC.
Reel/Frame 010779/0940 →
Assignment of Assignor's Interest
May 8, 2000
From: HUNT, TERRENCE J.
To: ALLERGAN SALES, INC.
Reel/Frame 010811/0585 →
Assignment of Assignor's Interest
Jul 24, 2000
From: MULLER, CHRISTOPHER A.; BANCROFT, ELIZABETH A.; CHEETHAM, JANET K.; JENSEN, HAROLD G.
To: ALLERGAN SALES, INC.
Reel/Frame 011004/0287 →
Assignment of Assignor's Interest
Jul 25, 2000
From: DONOVAN, STEPHEN
To: ALLERGAN SALES, INC.
Reel/Frame 011004/0227 →
Corrective Assignment to Correct the Name of the Assignee, Filed on 4-20-2000, Recorded on Ree 10755 Frame 0358 Assignor Hereby Confirms the Assignment of the Entire Interest.
Aug 3, 2000
From: PACIFICI, MAURIZIO; CHANDRARATNA, ROSHANTHA A.
To: ALLERGAN SALES, INC.
Reel/Frame 011136/0972 →
Assignment of Assignor's Interest
Aug 17, 2000
From: NEHME, ALISSAR; BEARD, RICHARD L.; CHANDRARATNA, ROSHANTHA A.
To: ALLERGAN SALES, INC.
Reel/Frame 011036/0795 →
Assignment of Assignor's Interest
Aug 22, 2000
From: SEFTON, JOHN
To: ALLERGAN SALES, INC.
Reel/Frame 011144/0193 →
Assignment of Assignor's Interest
Aug 24, 2000
From: FORMAN, BARRY M.
To: CITY OF HOPE NATIONAL MEDICAL CENTER
Reel/Frame 011142/0541 →
Assignment of Assignor's Interest
Aug 28, 2000
From: BEARD, RICHARD L.; CHANDRARATNA, ROSHANTHA A.
To: ALLERGAN SALES, INC.
Reel/Frame 011144/0184 →
Assignment of Assignor's Interest
Oct 20, 2000
From: DONOVAN, STEPHEN
To: ALLERGAN SALES, INC.
Reel/Frame 011283/0076 →
Assignment of Assignor's Interest
Nov 3, 2000
From: HUANG, DEHUA
To: ALLERGAN SALES, INC.
Reel/Frame 011233/0719 →